@antibotter did you really just tell the forum the following?:
‘Starpharma recently completed independent market research with US Physicians / Ophthalmologists and Payers regarding the opportunity for SPL7013 ophthalmic drops. Findings from the research were extremely positive and have been of particular interest in discussions with potential partners.’ ~@antibotter
I’m sorry everyone but IMO this is a blatant ramp. This quote by @antibotter was lifted word for word from a slide in a Starpharma update in JANUARY 2019.
Five years ago:
And the truth is that after tantalising shareholders every year with the prospect of SPL7013 entering the clinic for viral conjunctivitis since 2014, shareholders were finally told at the 2022 AGM that this project was no longer a priority and essentially was not going to be progressed.
In my opinion @antibotter, an apology to the forum is warranted for a misleading post. As you are a significant shareholder of longstanding in SPL, I believe this type of post is designed to create excitement amongst less knowledgeable shareholders and is unethical.
SPL Price at posting:
17.0¢ Sentiment: Sell Disclosure: Not Held
